TY - JOUR
T1 - Outlook for new car-based therapies with a focus on car nk cells
T2 - What lies beyond car-engineered t cells in the race against cancer
AU - Daher, May
AU - Rezvani, Katayoun
N1 - Funding Information:
This work was supported by the generous philanthropic support of the MD Anderson Cancer Center Moon Shots Program, by grants from CPRIT (RP160693), the Leukemia Lymphoma Society (6555- 18), by a Stand Up To Cancer Dream Team Research Grant (grant number: SU2C-AACR-DT-29-19), by grants (1 R01 CA211044-01, 5 P01CA148600-03, and P50CA100632-16) from the NIH, and by a grant (CA016672) to the MD Anderson Cancer Center from the NIH. The SU2C research grant is administered by the American Association for Cancer Research, the scientific partner of SU2C.
Publisher Copyright:
© 2020 American Association for Cancer Research.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Chimeric antigen receptor (CAR) engineering of T cells has revolutionized the field of cellular therapy for the treatment of cancer. Despite this success, autologous CAR-T cells have recognized limitations that have led to the investigation of other immune effector cells as candidates for CAR modification. Recently, natural killer (NK) cells have emerged as safe and effective platforms for CAR engineering. In this article, we review the advantages, challenges, and preclinical and clinical research advances in CAR NK cell engineering for cancer immunotherapy. We also briefly consider the feasibility and potential benefits of applying other immune effector cells as vehicles for CAR expression. Significance: CAR engineering can redirect the specificity of immune effector cells, converting them to a much more potent weapon to combat cancer cells. Expanding this strategy to immune effectors beyond conventional T lymphocytes could overcome some of the limitations of CAR T cells, paving the way for safer and more effective off-the-shelf cellular therapy products.
AB - Chimeric antigen receptor (CAR) engineering of T cells has revolutionized the field of cellular therapy for the treatment of cancer. Despite this success, autologous CAR-T cells have recognized limitations that have led to the investigation of other immune effector cells as candidates for CAR modification. Recently, natural killer (NK) cells have emerged as safe and effective platforms for CAR engineering. In this article, we review the advantages, challenges, and preclinical and clinical research advances in CAR NK cell engineering for cancer immunotherapy. We also briefly consider the feasibility and potential benefits of applying other immune effector cells as vehicles for CAR expression. Significance: CAR engineering can redirect the specificity of immune effector cells, converting them to a much more potent weapon to combat cancer cells. Expanding this strategy to immune effectors beyond conventional T lymphocytes could overcome some of the limitations of CAR T cells, paving the way for safer and more effective off-the-shelf cellular therapy products.
UR - http://www.scopus.com/inward/record.url?scp=85100254406&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100254406&partnerID=8YFLogxK
U2 - 10.1158/2159-8290.CD-20-0556
DO - 10.1158/2159-8290.CD-20-0556
M3 - Review article
C2 - 33277313
AN - SCOPUS:85100254406
SN - 2159-8274
VL - 11
SP - 45
EP - 58
JO - Cancer discovery
JF - Cancer discovery
IS - 1
ER -